The histopathological spectrum of human meningiomas

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 3, 2012, Pages 231-242

  Backer Grøndahl, Thomas ^a   Moen, Bjørnar H ^a   Torp, Sverre H ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Brain tumors; Classification; Clemmesen's hook; Diagnosis; Grading

Indexed keywords

ARTICLE; CANCER GRADING; CANCER INVASION; CHI SQUARE DISTRIBUTION; CLASSIFICATION; COMPARATIVE STUDY; FEMALE; GENETICS; HUMAN; MALE; MENINGIOMA; MIDDLE AGED; MUTATION; NORWAY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY; TIME;

CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NORWAY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84861210178     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Perry A, Louis DN, Scheithauer BW, Budka H and von Deimling A. The 2007 WHO classification of tumours of the central nervous system. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P, editors. Acta Neuropathol 2007; pp: 97-109.
2. CBTRUS TCBTRotUS. Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. 2011.
3. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M and Black PM. Epidemiology of intracranial meningioma. Neurosurgery 2005; 57: 1088-1095; discussion 1088-1095.
4. Perry A, Brat, Daniel J. Meningiomas. In: Arie Perry DJB, editors. Practical Surgical Neuropathology: A Diagnostic Approch. Churchill Livingstone Elsevier; 2010.
5. Maiuri F, De Caro Mdel B, Esposito F, Cappabianca P, Strazzullo V, Pettinato G and de Divitiis E. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J Neurooncol 2007; 82: 63-68.
6. Commins DL, Atkinson RD and Burnett ME. Review of meningioma histopathology. Neurosurg Focus 2007; 23: E3.
7. Torp SH, Lindboe CF, Gronberg BH, Lydersen S and Sundstrom S. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas. Clin Neuropathol 2005; 24: 170-174.
8. Perry A, Stafford SL, Scheithauer BW, Suman VJ and Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 1997; 21: 1455-1465.
9. Skullerud K, Løken AC. The prognosis in meningiomas. Acta neuropathologica 1974; 29: 337-344.
10. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957; 20: 22-39.
11. Jaaskelainen J, Haltia M and Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 1986; 25: 233-242.
12. Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol 2010; 99: 379-391.
13. Lamszus K. Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 2004; 63: 275-286.
14. Campbell BA, Jhamb A, Maguire JA, Toyota B and Ma R. Meningiomas in 2009: controversies and future challenges. Am J Clin Oncol 2009; 32: 73-85.
15. Miller DC. Meningiomas. In: Miller DC, editors. Modern surgical pathology. Cambridge university press. 2009; pp: 217-236.
16. Willis J, Smith C, Ironside JW, Erridge S, Whittle IR and Everington D. The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol 2005; 31: 141-149.
17. Rogers L, Gilbert M and Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol 2010; 99: 393-405.
18. Statistics-Norway. SSB: Population, by sex, age and municipality. 1. January 2011. 2011.
19. Trembath D, Miller CR and Perry A. Gray zones in brain tumor classification: evolving concepts. Adv Anat Pathol 2008; 15: 287-297.
20. Quinn CM, Wright NA. The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. The Journal of pathology 1990; 160: 93-102.
21. Perry A. Meningiomas. In: McLendon RE, Rosenblum MK, Bigner DD, editors. Russell & Rubinstein's Pathology of Tumors of the Nervous System. Seventh. Oxford University Press Inc. 2006; pp: 427-474.
22. de la Monte SM, Flickinger J and Linggood RM. Histopathologic features predicting recurrence of meningiomas following subtotal resection. The American journal of surgical pathology 1986; 10: 836-843.
23. Burger CP, Scheithauer, B. W. Meningiomas. Washington DC: American Registry of Pathology in collaboration with the Armed Forces of Pathology, 2007.
24. Perry A, Scheithauer BW, Stafford SL, Lohse CM and Wollan PC. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 1999; 85: 2046-2056.
25. Mahmood A, Caccamo DV, Tomecek FJ and Malik GM. Atypical and malignant meningiomas: a clinicopathological review. Neurosurgery 1993; 33: 955-963.
26. Kane AJ, Sughrue ME, Rutkowski MJ, Shangari G, Fang S, McDermott MW, Berger MS and Parsa AT. Anatomic Location Is a Risk Factor for Atypical and Malignant Meningiomas. Cancer 2011; 117: 1272-1278.
27. Roser F, Nakamura M, Bellinzona M, Rosahl SK, Ostertag H and Samii M. The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol 2004; 57: 1033-1037.
28. Wolfsberger S, Doostkam S, Boecher-Schwarz HG, Roessler K, van Trotsenburg M, Hainfellner JA and Knosp E. Progesterone-receptor index in meningiomas: correlation with clinicopathological parameters and review of the literature. Neurosurg Rev 2004; 27: 238-245.
29. Anderson WF, Pfeiffer RM, Dores GM and Sherman ME. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer epidemiol Biomarkers Prev 2006; 15: 1899-1905.
30. Clemmesen J. Carcinoma of the breast; results from statistical research. The British journal of radiology 1948; 21: 583-590.
31. Maier H, Ofner D, Hittmair A, Kitz K and Budka H. Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 1992; 77: 616-623.
32. Kasuya H, Kubo O, Tanaka M, Amano K, Kato K and Hori T. Clinical and radiological features related to the growth potential of meningioma. Neurosurgical review 2006; 29: 293-296; discussion 296-297.
33. O'Rahilly R, Muller F. The meninges in human development. J Neuropathol Exp Neurol 1986; 45: 588-608.
34. Catala M. Embryonic and fetal development of structures associated with the cerebro-spinal fluid in man and other species. Part I: The ventricular system, meninges and choroid plexuses. Archives d'anatomie et de cytologie pathologiques 1998; 46: 153-169.
35. Uzum N, Ataoglu GA. Histopathological parameters with Ki-67 and bcl-2 in the prognosis of meningiomas according to WHO 2000 classification. Tumori 2008; 94: 389-397.
36. Berry M, Bannister LH and Standring SM. Nervous System. In: editors. Gray's Anatomy. 38th. Churchill Livingstone. 1995; pp: 1209-1218.
37. Ayerbe J, Lobato RD, de la Cruz J, Alday R, Rivas JJ, Gomez PA and Cabrera A. Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. Acta Neurochir (Wien) 1999; 141: 921-932.
38. Pearson BE, Markert JM, Fisher WS, Guthrie BL, Fiveash JB, Palmer CA and Riley K. Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurgical focus 2008; 24: E3.
39. Vranic A, Popovic M, Cor A, Prestor B and Pizem J. Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients. Neurosurgery 2010; 67: 1124-1132.
40. Miller DC. Predicting recurrence of intracranial meningiomas. A multivariate clinicopathologic model-interim report of the New York University Medical Center Meningioma Project. Neurosurgery clinics of North America 1994; 5: 193-200.
41. Ho DM, Hsu CY, Ting LT and Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 2002; 94: 1538-1547.
42. Prayson RA. Cell proliferation and tumors of the central nervous system. Part 1: Evaluation of mitotic activity. Journal of Neuropathology and Experimental Neurology 2002; 61: 501-509.
43. Kim YJ, Ketter R, Steudel WI and Feiden W. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol 2007; 128: 118-125.
44. Ribalta T, McCutcheon IE, Aldape KD, Bruner JM and Fuller GN. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol 2004; 28: 1532-1536.
45. Torp SH, Lindboe CF, Granli US, Moen TM and Nordtomme T. Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas. Clin Neuropathol 2001; 20: 190-195.
46. Abramovich CM, Prayson RA. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Archives of pathology & laboratory medicine 1999; 123: 793-800.
47. Ng HK, Poon WS, Goh K and Chan MS. Histopathology of post-embolized meningiomas. The American journal of surgical pathology 1996; 20: 1224-1230.
48. McLean CA, Jolley D, Cukier E, Giles G and Gonzales MF. Atypical and malignant meningiomas: importance of micronecrosis as a prognostic indicator. Histopathology 1993; 23: 349-353.
49. Ironside JW, Moss TH, Louis DN, Lowe JS and Weller RO. Meningiomas. In: Ironside JW, Moss TH, Louis DN, Lowe JS, Weller RO, editors. Diagnostic Pathology of Nervous System Tumours Edinburgh: CHURCHILL LIVINGSTONE. 2002; pp: 344-382.
50. Ng HK, Chen L. Apoptosis is associated with atypical or malignant change in meningiomas. An in situ labelling and immunohistochemical study. Histopathology 1998; 33: 64-70.
51. Abramovich CM, Prayson RA. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome. American Journal of Clinical Pathology 2000; 114: 84-92.
52. Konstantinidou AE, Givalos N, Gakiopoulou H, Korkolopoulou P, Kotsiakis X, Boviatsis E, Agrogiannis G, Mahera H and Patsouris E. Caspase-3 immunohistochemical expression is a marker of apoptosis, increased grade and early recurrence in intracranial meningiomas. Apoptosis 2007; 12: 695-705.
53. Torp SH, Helseth E, Dalen A and Unsgaard G. Expression of epidermal growth factor receptor in human meningiomas and meningeal tissue. APMIS 1992; 100: 797-802.
54. Blaine SA, Ray KC, Branch KM, Robinson PS, Whitehead RH and Means AL. Epidermal growth factor receptor regulates pancreatic fibrosis. American journal of physiology. Gastrointestinal and liver physiology 2009; 297: G434-441.
55. Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A and Park JE. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 2007; 29: 976-985.
56. Wernicke AG, Dicker AP, Whiton M, Ivanidze J, Hyslop T, Hammond EH, Perry A, Andrews DW and Kenyon L. Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Radiat Oncol 2010; 5: 46.
57. Hardie WD, Davidson C, Ikegami M, Leikauf GD, Le Cras TD, Prestridge A, Whitsett JA and Korfhagen TR. EGF receptor tyrosine kinase inhibitors diminish transforming growth factoralpha-induced pulmonary fibrosis. American journal of physiology. Lung cellular and molecular physiology 2008; 294: L1217-1225.
58. Machein MR, Plate KH. VEGF in brain tumors. Journal of Neuro-Oncology 2000; 50: 109-120.
59. Schmid S, Aboul-Enein F, Pfisterer W, Birkner T, Stadek C and Knosp E. Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients. Neurosurgery 2010; 67: 1703-1708; discussion 1708.
60. Ruiz J, Martinez A, Hernandez S, Zimman H, Ferrer M, Fernandez C, Saez M, Lopez-Asenjo JA and Sanz-Ortega J. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II. Histol Histopathol 2010; 25: 341-349.
61. Bo L, Mork SJ and Nyland H. An immunohistochemical study of mononuclear cells in meningiomas. Neuropathology and Applied Neurobiology 1992; 18: 548-558.
62. Rossi ML, Cruz Sanchez F, Hughes JT, Esiri MM and Coakham HB. Immunocytochemical study of the cellular immune response in meningiomas. Journal of clinical pathology 1988; 41: 314-319.